AOD 9604 vs Mots-C: How These Research Peptides Compare

AOD 9604 and Mots-C are both research peptides that scientists study for metabolic effects, but they belong to different chemical families and work through distinct pathways. AOD 9604 is a synthetic fragment of human growth hormone (HGH) that has been investigated for fat loss, while Mots-C is a mitochondrial-derived peptide studied for insulin sensitivity and exercise-like metabolic changes. Neither peptide is FDA-approved for human use in the United States, and both are sold strictly for laboratory research.

What Is AOD 9604?

AOD 9604 (also written AOD-9604) is a 16-amino-acid peptide that matches the fat-releasing region of HGH, amino acids 176-191. Researchers designed it to capture HGH's lipolytic effects without triggering growth or blood sugar changes. Early human trials in the 1990s and 2000s tested AOD 9604 for obesity, but the results were modest and it never received regulatory approval for weight loss.

• Origin: Modified fragment of human growth hormone (HGH 176-191)
• Primary research focus: Fat metabolism, lipolysis, obesity
• Human data: Several small clinical trials; no large phase 3 outcomes
• FDA status: Not approved for any human use
• Common research dose: Often 250–500 mcg per day by subcutaneous injection in published studies, but no standard human dose exists

What Is Mots-C?

Mots-C is a mitochondrial-derived peptide, which means it is encoded by DNA inside the mitochondria rather than the cell nucleus. It was first described in 2015 and is sometimes called an "exercise mimetic" because it helps regulate metabolic pathways that respond to physical activity. Animal studies show Mots-C can improve glucose tolerance, increase insulin sensitivity, and reduce fat accumulation, especially in mice fed a high-fat diet.

• Origin: Mitochondrial genome (12S rRNA region)
• Primary research focus: Insulin sensitivity, glucose metabolism, exercise response
• Human data: Very limited; mostly animal and cell studies
• FDA status: Not approved for human use
• Common research dose: 5–10 mg per week divided into 2–3 subcutaneous injections in some reported protocols, but no standardized human dose exists

AOD 9604 vs Mots-C: Side-by-Side Comparison

How Do They Compare for Fat Loss?

There are no head-to-head studies comparing AOD 9604 and Mots-C for fat loss in humans. AOD 9604 has been tested directly in human trials for obesity, though the effects were not dramatic. Mots-C has stronger preclinical data for improving metabolic markers, but human fat-loss data is almost nonexistent. Neither peptide is a proven weight-loss treatment.

Researchers often look at other peptides in the same conversation. For example, aod 9604 vs tesamorelin contrasts a GH fragment with a GHRH analog that is FDA-approved for HIV-related lipodystrophy. You may also see aod 9604 vs retatrutide, though retatrutide is a triple receptor agonist still in clinical trials, not a peptide fragment. For recovery and growth hormone stacks, aod-9604 vs cjc-1295 ipamorelin is a common pairing. A smaller-molecule option appears in 5-amino-1mq vs aod-9604, which compares a fat-metabolism compound to the HGH fragment. A broader overview might cover aod 9604 mots-c tesamorelin as three distinct metabolic research peptides.

Safety, Side Effects, and Legal Status

Both AOD 9604 and Mots-C are sold as research chemicals, not as dietary supplements or prescription drugs. The FDA has not approved either peptide for human use, so products labeled for human consumption are illegal to market. Potential side effects reported in studies or user reports include injection site reactions, headache, nausea, and changes in blood sugar. Mots-C may lower blood glucose, which could interact with diabetes medications.

• Not FDA-approved for human use
• Not legal to sell as a drug or supplement
• Purity and dosing are unregulated in the research market
• Consult a licensed healthcare professional before using any research peptide

Bottom Line

AOD 9604 and Mots-C are different tools studied for different metabolic goals. AOD 9604 is an HGH fragment with some human data on fat loss. Mots-C is a mitochondrial peptide with promising animal data on insulin sensitivity and exercise metabolism. Neither is a proven or approved treatment for any condition. If you are considering either peptide, talk to a licensed healthcare provider and prioritize safety over internet claims.